Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Mallinckrodt
Federal Trade Commission
Accenture
Fish and Richardson
Julphar
Teva
Cantor Fitzgerald

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021152

« Back to Dashboard

NDA 021152 describes CUTIVATE, which is a drug marketed by Fougera Pharms and is included in three NDAs. It is available from four suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the CUTIVATE profile page.

The generic ingredient in CUTIVATE is fluticasone propionate. There are twenty-six drug master file entries for this compound. Eighty-three suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
Summary for 021152
Tradename:CUTIVATE
Applicant:Fougera Pharms
Ingredient:fluticasone propionate
Patents:1
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Respiratory Tract Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 021152
Suppliers and Packaging for NDA: 021152
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CUTIVATE fluticasone propionate LOTION;TOPICAL 021152 NDA AUTHORIZED GENERIC E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. 0168-0434 N 0168-0434-04
CUTIVATE fluticasone propionate LOTION;TOPICAL 021152 NDA AUTHORIZED GENERIC E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. 0168-0434 N 0168-0434-60

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:LOTION;TOPICALStrength0.05%
Approval Date:Mar 31, 2005TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Jan 16, 2018
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Patent:➤ Try a Free TrialPatent Expiration:Oct 20, 2019Product Flag?YSubstance Flag?Delist Request?
Patented Use:RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Queensland Health
Chinese Patent Office
Healthtrust
Moodys
Chubb
Julphar
Fish and Richardson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.